Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study
We observed a high drug burden in mBC patients, largely due to treatment for comorbidities. These drugs might not only be associated with additional risk for side effects, pDDI, or PIM use, yet might also contribute to low medication adherence, higher medication costs and impaired QoL. Considering the burden of mBC and the predicted life expectancy, mBC patients might benefit from closer monitoring of their medication.
Authors
- Max Müller-Reiter
- Anna Grau
- Peter U. Heuschmann (ORCID: https://orcid.org/0000-0002-2681-3515)
- J Salmen
- Lilly Brandstetter (ORCID: https://orcid.org/0000-0003-0158-5402)
- Jens‐Peter Reese (ORCID: https://orcid.org/0000-0003-3545-2552)
- Achim Wöckel (ORCID: https://orcid.org/0000-0002-6767-9666)
- Stefan Störk (ORCID: https://orcid.org/0000-0002-1771-7249)
Institutions
- University of Würzburg (DE)
- Zimmer Biomet (Germany) (DE)
- Universitätsklinikum Würzburg (DE)
- Technische Hochschule Mittelhessen (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s12885-025-13548-8
- Citations
- 1
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.22
Funders
- Julius-Maximilians-Universität Würzburg
- Berlin Institute of Health